Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients

Arthritis and Rheumatism

Volumn 62, Issue 1, 2010, Pages 44-52

  Snir, Omri ^a   Widhe, Mona ^a   Hermansson, Monika ^a   Von Spee, Caroline ^a   Lindberg, Johan ^b   Hensen, Sanne ^a   Lundberg, Karin ^c   Engström, Åke ^d   Venables, Patrick J W ^c   Toes, René E M ^e   Holmdahl, Rikard ^f,g   Klareskog, Lars ^a   Malmström, Vivianne ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b ALBANOVA UNIVERSITY CENTER   (Sweden)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UPPSALA UNIVERSITY   (Sweden)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f Turku University   (Finland)

^g KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ENOLASE; COLLAGEN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; EPITOPE; FIBRINOGEN; HLA DR ANTIGEN; TETANUS TOXOID; VIMENTIN;

ADULT; AGED; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY REACTION; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; FEMALE; GENOTYPE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SEX DIFFERENCE; SYNOVIAL FLUID;

ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; AUTOANTIGENS; CITRULLINE; COLLAGEN TYPE II; DNA-BINDING PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOGEN; GENOTYPE; HLA-DR ANTIGENS; HUMANS; MALE; MIDDLE AGED; MUTATION; PEPTIDES, CYCLIC; PHOSPHOPYRUVATE HYDRATASE; SYNOVIAL FLUID; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; VIMENTIN; YOUNG ADULT;

EID: 74849107568     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.25036     Document Type: Article

References (29)

1. Klareskog L, Ronnelid J, Lundberg K, Padyukov L, Alfredsson L. Immunity to citrullinated proteins in rheumatoid arthritis. Annu Rev Immunol 2008;26:651-75.
2. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003;48:2741-9.
3. Ronnelid J, Wick MC, Lampa J, Lindblad S, Nordmark B, Klareskog L, et al. Longitudinal analysis of citrullinated protein/ peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis 2005;64: 1744-9.
4. Plenge RM, Padyukov L, Remmers EF, Purcell S, Lee AT, Karlson EW, et al. Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4. Am J Hum Genet 2005;77:1044-60.
5. Kallberg H, Padyukov L, Plenge RM, Ronnelid J, Gregersen PK, van der Helm-van Mil AH, et al. Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. Am J Hum Genet 2007;80: 867-75.
6. Van der Helm-van Mil AH, Huizinga TW. Advances in the genetics of rheumatoid arthritis point to subclassification into distinct disease subsets [review]. Arthritis Res Ther 2008;10:205.
7. Snir O, Widhe M, von Spee C, Lindberg J, Padyukov L, Lundberg K, et al. Multiple antibody reactivities to citrullinated antigens in sera from rheumatoid arthritis patients: association with HLA-DRB1 alleles. Ann Rheum Dis 2009;68:736-43.
8. Verpoort KN, Cheung K, Ioan-Facsinay A, van der Helm-van Mil AH, de Vries-Bouwstra JK, Allaart CF, et al. Fine specificity of the anti-citrullinated protein antibody response is influenced by the shared epitope alleles. Arthritis Rheum 2007;56:3949-52.
9. Burkhardt H, Sehnert B, Bockermann R, Engstrom A, Kalden JR, Holmdahl R. Humoral immune response to citrullinated collagen type II determinants in early rheumatoid arthritis. Eur J Immunol 2005;35:1643-52.
10. Auger I, Sebbag M, Vincent C, Balandraud N, Guis S, Nogueira L, et al. Influence of HLA-DR genes on the production of rheumatoid arthritis-specific autoantibodies to citrullinated fibrinogen. Arthritis Rheum 2005;52:3424-32.
11. Kinloch A, Tatzer V, Wait R, Peston D, Lundberg K, Donatien P, et al. Identification of citrullinated α-enolase as a candidate autoantigen in rheumatoid arthritis. Arthritis Res Ther 2005;7: R1421-9.
12. Burkhardt H, Koller T, Engstrom A, Nandakumar KS, Turnay J, Kraetsch HG, et al. Epitope-specific recognition of type II collagen by rheumatoid arthritis antibodies is shared with recognition by antibodies that are arthritogenic in collagen-induced arthritis in the mouse. Arthritis Rheum 2002;46:2339-48.
13. Burkhardt H, Huffmeier U, Spriewald B, Bohm B, Rau R, Kallert S, et al. Association between protein tyrosine phosphatase 22 variant R620W in conjunction with the HLA-DRB1 shared epitope and humoral autoimmunity to an immunodominant epitope of cartilage-specific type II collagen in early rheumatoid arthritis. Arthritis Rheum 2006;54:82-9.
14. Bang H, Egerer K, Gauliard A, Luthke K, Rudolph PE, Fredenhagen G, et al. Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum 2007; 56:2503-11.
15. Mathsson L, Mullazehi M, Wick MC, Sjoberg O, van Vollenhoven R, Klareskog L, et al. Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis Rheum 2008;58:36-45.
16. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
17. Senshu T, Akiyama K, Kan S, Asaga H, Ishigami A, Manabe M. Detection of deiminated proteins in rat skin: probing with a monospecific antibody after modification of citrulline residues. J Invest Dermatol 1995;105:163-9.
18. Lundberg K, Kinloch A, Allison H, Sriskandan S, Moyes D, Venables PJ. Mapping of citrullinated α-enolase antibodies to an immunodominant epitope with high sequence similarity to bacterial enolase. Ann Rheum Dis 2007;66 Suppl I:A6-69.
19. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998;95:14863-8.
20. Klareskog L, Widhe M, Hermansson M, Ronnelid J. Antibodies to citrullinated proteins in arthritis: pathology and promise. Curr Opin Rheumatol 2008;20:300-5.
21. Van der Helm-van Mil AH, Huizinga TW, de Vries RR, Toes RE. Emerging patterns of risk factor make-up enable subclassification of rheumatoid arthritis [review]. Arthritis Rheum 2007;56: 1728-35.
22. Klareskog L, Stolt P, Lundberg K, Kallberg H, Bengtsson C, Grunewald J, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006;54:38-46.
23. Dejaco C, Klotz W, Larcher H, Duftner C, Schirmer M, Herold M. Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis. Arthritis Res Ther 2006;8:R119.
24. Verpoort KN, Jol-van der Zijde CM, Papendrecht-van der Voort EA, Ioan-Facsinay A, Drijfhout JW, van Tol MJ, et al. Isotype distribution of anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response. Arthritis Rheum 2006;54:3799-808.
25. Kuhn KA, Kulik L, Tomooka B, Braschler KJ, Arend WP, Robinson WH, et al. Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J Clin Invest 2006;116:961-73.
26. Uysal H, Bockermann R, Nandakumar KS, Sehnert B, Bajtner E, Engstrom A, et al. Structure and pathogenicity of antibodies specific for citrullinated collagen type II in experimental arthritis. J Exp Med 2009;206:449-62.
27. Vossenaar ER, Smeets TJ, Kraan MC, Raats JM, van Venrooij WJ, Tak PP. The presence of citrullinated proteins is not specific for rheumatoid synovial tissue. Arthritis Rheum 2004;50:3485-94.
28. Hill JA, Southwood S, Sette A, Jevnikar AM, Bell DA, Cairns E. Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol 2003;171:538-41.
29. Hill JA, Bell DA, Brintnell W, Yue D, Wehrli B, Jevnikar AM, et al. Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic mice. J Exp Med 2008;205: 967-79.